Fabrication of triple-layer matrix tablets of venlafaxine hydrochloride using xanthan gum

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 624-630

  Gohel, Mukesh C ^a   Bariya, Shital H ^a  

^a L M COLLEGE OF PHARMACY   (India)

Author keywords

Layered tablet; Radar diagram; Venlafaxine hydrochloride; Weibull model; Xanthan gum

Indexed keywords

VENLAFAXINE; WATER; XANTHAN; ANTIDEPRESSANT AGENT; BACTERIAL POLYSACCHARIDE; CYCLOHEXANOL DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG GRANULATION; DRUG SOLUBILITY; IN VITRO STUDY; MATRIX TABLET; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TABLET COMPRESSION; TABLET MANUFACTURE; WATER TRANSPORT; CHEMISTRY; DELAYED RELEASE FORMULATION; SOLUBILITY; TABLET;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHEMISTRY, PHARMACEUTICAL; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; POLYSACCHARIDES, BACTERIAL; SOLUBILITY; TABLETS;

EID: 67549134673     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9244-z     Document Type: Article

References (34)

1. Lin SY, Lin TL. Different types of direct compressible excipients affecting the release behavior of theophylline controlled-release tablets containing eudragit resins. Drug Dev Ind Pharm 1993;19:1613-21.
2. Durig T, Fassihi R. Guar-based monolithic matrix systems: Effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. J Control Rel 2002;80:45-56.
3. Peppas NA, Gurny R, Doelker E, Buri P. Modelling of drug diffusion through swellable polymeric systems. J Membr Sci 1980;7:241-53.
4. Lachke A. Xanthan- A Versatile Gum. Resonance 2004;9:25-33.
5. Talukdar MM, Mooter VD, Augustijns P, Maga TT, Verbeke N, Kinget R. In vitro evaluation of xanthan gum as a potential excipient for oral controlled release matrix tablet formulation. Int J Pharm 1998;169:105-13.
6. Talukdar MM, Vercammen JP. Evaluation of xanthan gum as a hydrophillic matrix for controlled release dosage forms. Drug Dev Ind Pharm 1993;19:1037-46.
7. Cox PJ, Khan KA, Munday DL, Sujja-areevath J. Development and evaluation of a multiple-unit oral sustained release dosage form for S (+)-ibuprofen: Preparation and release kinetics. Int J Pharm 1999;193:73-84.
8. Billa N, Yuen KH. Formulation variables affecting drug release from xanthan gum matrices at laboratory scale and pilot scale. AAPS PharmSciTech 2000;1:35-42.
9. Munday DL, Cox PJ. Compressed xanthan and karaya gum matrices: hydration, erosion and drug release mechanisms. Int J Pharm 2000;203:179-92.
10. Tobyn MJ, Staniforth JN, Baichwal AR, McCall TW. Prediction of physical properties of a novel polysaccharide controlled release system. Int J Pharm 1996;128:113-22.
11. Sujja-areevath J, Munday DL, Cox PJ, Khan KA. Relationship between swelling, erosion and drug release in hydrophilic natural gum mini-matrix formulations. Eur J Pharm Sci 1998;6:207-17.
12. Lu MF, Woodward L, Borodkin S. Xanthan Gum and Alginate Based Controlled Release Theophylline Formulations. Drug Dev Ind Pharm 1991;17:1987-2004.
13. Dhopeshwarkar V, O'Keeffe JC, Zatz JL, Deete R, Horton M. Development of an Oral Sustained-Release Antibiotic Matrix Tablet Using In Vitro - In Vivo Correlations. Drug Dev Ind Pharm 1994;20:1851-67.
14. Watanabe K, Yakou S, Takayama K, Machida Y, Nagai T. Factors affecting prednisolone release from hydrogels prepared with water-soluble dietary fibers, xanthan and locust bean gums. Chem Pharm Bull 1992;40:459-62.
15. Watanabe K, Yakou S, Takayama K, Machida Y, Isowa K, Nagai T. Investigation on rectal absorption of indomethacin from sustained-release hydrogel suppositories prepared with water-soluble dietary fibers, xanthan gum and locust bean gum. Biol Pharm Bull 1993;16:391-4.
16. Yeole PG, Galgatte UC, Babla IB, Nakhat PD. Design and evaluation of Xanthan gum-based sustained release Matrix tablets of Diclofenac sodium. Indian J Pharm Sci 2006;68:185-9.
17. Nicholas TW, Jones L, Chamberlain JC. A possible case of venlafaxine-induced Stevens-Johnson syndrome. J Clin Psychiatry 2004;65:1431-2.
18. Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: A comparative analysis. Hum Psychopharmacol 2004;19:9-16.
19. Gohel MC, Patel TP, Bariya SH. Studies in preparation and evaluation of pH-independent sustained-release matrix tablets of verapamil HCl using directly compressible eudragits. Pharm Dev Technol 2003;8:323-33.
20. Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm 2001;220:77-83.
21. Higuchi T. Mechanisms of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145-9.
22. Ertan G, Karasulu HY, Karasulu E, Ege MA, Kose T, Guneri T. A new in vitro/in vivo kinetic correlation method for nitrofurantoin matrix tablet formulations. Drug Dev Ind Pharm 2000;26:737-43.
23. Langenbucher F. Linearization of dissolution rate curve by the Weibull distribution. J Pharm Pharmacol 1972;24:979-81.
24. Gohel MC, Parikh RK, Padshala MN, Sarvaiya KG, Jena DG. Formulation and optimization of directly compressible isoniazid modified release matrix tablet. Indian J Pharm Sci 2007;69:640-5.
25. Roy DS, Rohera BD. Comparative evaluation of rate of hydration and matrix erosion of HEC and HPC and study of drug release from their matrices. Eur J Pharm Sci 2002;16:193-9.
26. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res 1998;15:889-96.
27. Shajahan A, Poddar SS. A flexible technology for modified release of drugs: Multi layered tablets. J control Rel 2004;97:393-405.
28. Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrixé multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996;17:889-96.
29. Maggi L, Bruni R, Conte U. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. Int J Pharm 2000;195:229-38.
30. Siahi MR, Jalali MB, Monajjemzadeh F, Ghaffari F, Azarmi S. Design and evaluation of 1- and 3-layer matrices of verapamil hydrochloride for sustaining its release. AAPS PharmSciTech 2005;6(4):EE626-EE32. doi: 10.1208/pt060477.
31. El-Nabarawi MA. Modulation of tenoxicam release from hydrophilic matrix: Modulator membrane versus rate-controlling membrane. Chem Pharm Bull 2005;53:1083-7.
32. FDA Alert for Healthcare Professionals (July 2005): Hydromorphone Hydrochloride Extended-Release Capsules (marketed as Palladone™). http://www.fda.gov/cder/drug/InfoSheets/HCP/hydromorphoneHCP.pdf (accessed 08/03/08), part of http://www.fda.gov (accessed 08/03/08).
33. Rowe RC, Sheskey PJ, Weller PJ. Xanthan gum. In: Rowe RC, Sheskey PJ, Weller PJ, editors. Handbook of pharmaceutical excipients, 4th edn. London: Pharmaceutical; 2003. p. 691-3.
34. Dokoumetzidis A, Papadopoulou V, Macheras P. Analysis of dissolution data using modified versions of noyes-whitney equation and the Weibull function. Pharm Res 2006;23:256-61.